Topic to explore potential impact of data driven personalization and robotics on Rx costs
DURHAM, NC – MAY 24 2017 –Panaceutics Inc., a personalized medicine and clinical nutrition company, today announced that Chief Executive Officer Edison Hudson will present at the Precision World Medicine Conference, PMWC-2017, on Thursday, May 25th at 2:15 pm at Duke University’s Fuqua School of Business. Recognized as the original and leading annual forum on precision medicine, this event attracts over 11,000 attendees to listen to presentations and panels made by the world’s leading authorities and experts across the health care and bioinformatics sectors. These experts are delivering the most current, up-to-date content across all facets of personalized and precision medicine.
“As a team, we are bringing cross-functional stakeholders of this exciting field together to exchange ideas and the learnings gathered so far that can be translated into new winning strategies for the future of precision medicine as cutting edge development in healthcare,” said PMWC-2017 program co-chair Geoff Ginsberg, M.D., Ph.D., Director of the Duke Center for Applied Genomics and Precision Medicine. The event will be launched on Wednesday, May 24th by North Carolina Governor Roy Cooper and Mary E. Klotman, Chair of the Duke University School of Medicine.
“I am honored to be part of this esteemed conference and among the professionals who are blazing the path toward commercializing precision medicine. My talk will focus on how personalized medicine could be a game changer for patient adherence, actionable while reducing prescription costs,” said Hudson.
Hudson is no stranger to inventing new technologies that automate complex tasks. Before co-founding Panaceutics to lead the team to design a novel automated personalized medicine fulfillment system, he was a leader in several technology and robotics companies, including iRobot, Adept Technology, and Redzone Robotics, spending over a decade in the semiconductor industry in Silicon Valley. Founder of four companies, he has more than 17 patents in machine design, control systems, machine vision, algorithms, and semiconductor processes. A Morehead Scholar at the University of North Carolina, he also studied artificial intelligence at Oxford University and received an MBA from Duke University.
About Panaceutics Inc.
Panaceutics delivers personalized monthly subscriptions of “pill free” suspensions combining up to 20 active macro and micro nutrient ingredients in tasty puree filled pouches that are a convenient way to take individualized formulas of clinical nutrition and pharmacy grade dietary supplements. In several market trials, this delivery form has been found to be favored by a large majority over taking multiple pills. Cloud-based software is used to choose the right ingredients and dosage for an individual, and the formula is then sent to Panaceutics’ proprietary robotic system that builds a 30-day supply in a few minutes under cGMP quality rules. Panaceutics, with the addition of recently acquired Triangle Compounding Pharmacy, gains expertise in pharmaceutical delivery and a 503B
outsourcing pharmacy facility. Dr. Michael Jay, Chairman of the Division of Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy heads the Company’s Advisory Board and along with several other distinguished medical professionals are advising co-founder Lloyd Staton Noel, III, a 20 year veteran of drug discovery at GSK, in the development and testing of the company’s patented and proprietary technologies applied to precision combination pharmaceutical therapies. In a joint development signed with a large hospital system’s cardiology team, the company will develop cardiovascular “poly therapies” including approved generic pharmaceutical ingredients individually formulated and combined in a form designed to dramatically improve adherence. Panaceutics’ formulation software and robotic small batch manufacturing technologies will enable the principles of precision medicine and health to be economically applied to large markets.
For additional information please contact:
Chief Executive Officer
Panaceutics Inc /
Panacea BioMatx Inc